Fuentes de información y búsqueda bibliográfica:

Anexo A del Programa MADRE versión 4.0 (pág. 96 a 112)

XI CURSO DE EVALUACIÓN Y SELECCIÓN DE MEDICAMENTOS

Servicios de Farmacia | Hospitales Virgen del Rocío y Son Espases

Antonio Monzón Moreno

Servicio de Farmacia

Hospital Universitario Virgen del Rocío

antonio.monzon.sspa@juntadeandalucia.es



ANEXO A

Fuentes de información y búsqueda bibliográfica

1- BÚSQUEDA DE DATOS ESTADÍSTICOS SOBRE SALUD

2- BÚSQUEDA DE GUÍAS DE PRÁCTICA CLÍNICA

3- BÚSQUEDA DE ENSAYOS CLÍNICOS

4- BÚSQUEDA DE REFERENCIAS DE REVISIONES Y METAANÁLISIS

5- BÚSQUEDA DE ESTUDIOS NO PUBLICADOS

6- BÚSQUEDA DE REFERENCIAS DE COMPARACIONES INDIRECTAS

7- BÚSQUEDA DE EVALUACIONES PREVIAS DEL MEDICAMENTO REALIZADAS POR ORGANISMOS INDEPENDIENTES

8- OPINIONES DE EXPERTOS

9- BÚSQUEDA DE REFERENCIAS DE ESTUDIOS OBSERVACIONALES

10- BÚSQUEDA DE INFORMACION SOBRE SEGURIDAD

11- BÚSQUEDA DE REFERENCIAS DE ESTUDIOS DE EVALUACIÓN ECONÓMICA



1. La ficha técnica y la discusión científica.
2. Evaluaciones realizadas por organismos independientes.
3. Metabuscadores
4. Ensayos clínicos publicados (fuentes primarias): el ensayo pivotal.
5. Base de datos de Ensayos Clínicos: Clinicaltrials.gov.
6. Guías de práctica clínica: Guía Salud, Fisterra, National Guideline Clearinghouse, NCCN.
7. Literatura gris e Internet invisible: Metabuscador Scirus.



1. La ficha técnica y la discusión científica.

Ensayos toxicidad, farmacocinéticos, ensayos fase III, pivotales, etc

Drug information:	European Public Assessment Report (EPAR):	Centro de Información de medicamentos:
- Patient Package Insert	-	- Prospecto
- Label (1 ó varias)	- EPAR - Product information (sólo 1)	- Ficha técnica (sólo 1)
- Review (1 ó varias)	- EPAR - Scientific Discussion (1 ó varias)	- En algunos casos redirige a EMA.

http://www.aemps.gob.es/



Número de Registro	Medicamento	Principios Activos	Laboratorio titular	Estado del medicamento	Condiciones de Prescripción y Uso	Estado comercialización	Información del Medicamento
04300001	AVASTIN 25 mg/ml CONCENTRADO PARA SOLUCION PARA PERFUSION - N.R.: 04300001	Bevacizumab	Roche Registration Limited	Autorizado 08/02/2005	Uso Hospitalario	Comercializado	FT P

1. NOMBRE DEL MEDICAMENTO

Avastin 25 mg/ml concentrado para solución para perfusión.

2. COMPOSICIÓN CUALITATIVA Y CUANTITATIVA

Cada ml de concentrado contiene 25 mg de bevacizumab.
Cada vial de 4 ml contiene 100 mg de bevacizumab, correspondiente a 1,4 mg/ml cuando se diluye según se recomienda.
Cada vial de 16 ml contiene 400 mg de bevacizumab, correspondiente a 16,5 mg/ml cuando se diluye según se recomienda.

Bevacizumab es un anticuerpo monoclonal humanizado producido por tecnología del ADN recombinante en células ováricas de hámster chino.

Para consultar la lista completa de excipientes, ver sección 6.1.

3. FORMA FARMACÉUTICA

Concentrado para solución para perfusión.

Líquido de incoloro a marrón pálido y de transparente a ligeramente opalescente.

4. DATOS CLÍNICOS

4.1 Indicaciones terapéuticas

Bevacizumab está indicado en combinación con quimioterapia basada en fluoropirimidinas para el tratamiento de pacientes adultos con carcinoma metastásico de colon o recto.

Bevacizumab está indicado en combinación con paclitaxel para el tratamiento en primera línea de pacientes adultos con cáncer de mama metastásico. Para más información sobre el estado del receptor 2 del factor de crecimiento epidérmico humano (HER2), ver sección 5.1.



http://www.ema.europa.eu/ema/

Centralised authorisation procedure

The centralised procedure is **compulsory** for:

- human medicines for the treatment of HIV/AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions, and viral diseases;
- veterinary medicines for use as growth or yield enhancers;
- medicines derived from biotechnology processes, such as genetic engineering;
- advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines;
- officially designated 'orphan medicines' (medicines used for rare human diseases).





Avastin bevacizumab

Avastin

bevacizumab

About | Authorisation details | Product information | Assessment history

Next tab »

This is a summary of the European public assessment report (EPAR) for Avastin. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Avastin.

Product information

21/02/2013 Avastin -EMEA/H/C/000582 -II/0057

Name	Language	First published	Last updated
Avastin : EPAR - Product Information	EN = English GO	17/09/2009	25/03/2013

Ficha técnica única, actualizada, en varios idiomas.

Initial marketing-authorisation documents

Name	Language	First published
Avastin : EPAR - Scientific Discussion	(English only)	24/01/2006
Avastin : EPAR - Procedural steps taken before authorisation	(English only)	24/01/2006

Changes since initial authorisation of medicine

Name	Language	First published
Avastin : EPAR - Procedural steps taken and scientific information after authorisation	(English only)	17/09/2009
CHMP post-authorisation summary of positive opinion for Avastin	(English only)	21/09/2012
CHMP post-authorisation summary of positive opinion for Avastin	(English only)	23/09/2011
CHMP post-authorisation summary of positive opinion for Avastin	(English only)	15/04/2011
Questions and answers on the recommendation for the refusal of a change to the marketing authorisation for Avastin	EN = English GO	19/11/2009
CHMP post-authorisation summary of positive opinion for Avastin	(English only)	18/02/2009

Nuevas evaluaciones, ampliación de indicaciones, etc.

XI CURSO DE EVALUACIÓN Y SELECCIÓN DE MEDICAMENTOS

Servicios de Farmacia | Hospitales Virgen del Rocío y San Espases

EPAR- Scientific Discussion:

Part I: Introducción:

La patología, incidencia, tratamientos actuales, etc.

Part II: Chemical, pharmaceutical and biological aspects:

Composición, estabilidad, fabricación, etc.

Part III: Toxico-pharmacological aspects:

Farmacología, farmacocinética, farmacodinamia (ADME), estudios toxicológicos.

Part IV: Clinical aspects:

Estudios farmacocinéticos (fase I).

Estudios de eficacia clínica (fase II ó III): respuesta, supervivencia, calidad de vida.

Estudios de seguridad: eventos adversos, resultados de laboratorio, poblaciones especiales (ancianos, pediátricos, insuficiencia renal, insuficiencia hepática).

Overall conclussions and benefit/risk assessment

Recommendation

References

http://www.fda.gov/

U.S. Department of **Health & Human Services**

a A A

A to Z Index | Follow FDA | FDA Voice Blog

SEARCH

Most Popular Searches

U.S. Food and Drug Administration

Protecting and Promoting *Your* Health

Home | Food | Drugs | Medical Devices | Radiation-Emitting Products | Vaccines, Blood & Biologics | Animal & Veterinary | Cosmetics | Tobacco Products

- Drug Information (Drugs@FDA)

Drugs@FDA

FDA Approved Drug Products

FAQ | Instructions | Glossary | Contact Us

Drugs@FDA Demo | What's New in Drugs@FDA

Search by Drug Name, Active Ingredient, or Application Number

Enter at least three characters: Submit Clear Advanced Search

Browse by Drug Name

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

XI CURSO DE EVALUACIÓN Y SELECCIÓN DE MEDICAMENTOS

Servicios de Farmacia | Hospitales Virgen del Rocío y San Espases

Drugs@FDA

FDA Approved Drug Products

FAQ | Instructions | Glossary | Contact Us

Start Over

Drug Details

Drug Name(s)	AVASTIN
FDA Application No.	(BLA) 125085
Active Ingredient(s)	BEVACIZUMAB
Company	GENENTECH
Original Approval or Tentative Approval Date	February 26, 2004

- There are no Therapeutic Equivalents
- Approval History, Letters, Reviews, and Related Documents
- Label Information
- Other Important Information from FDA



Orden cronológico

Action Date	Supplement Number	Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note
01/23/2013	263	New or Modified Indication	Label (PDF) Letter (PDF)	
11/20/2012	265	Labeling Revision	Label (PDF) Letter (PDF)	
10/26/2012	239	Efficacy Supplement with Clinical Data to Support	Label (PDF) Letter (PDF)	
05/03/2012	0238	Supplement	Label (PDF) Letter (PDF)	
12/20/2011	0241	Supplement	Letter (PDF)	Label is not available on this site.
09/30/2011	225	Supplement	Label (PDF) Letter (PDF)	
02/08/2011	208	Supplement	Letter (PDF)	Label is not available on this site.
12/28/2010	204	Supplement	Letter (PDF)	Label is not available on this site.
07/31/2009	0168	Supplement	Label (PDF) Letter (PDF)	
05/05/2009	0169	Supplement	Label (PDF) Letter (PDF)	
03/10/2008	0145	Supplement	Label (PDF) Letter (PDF)	
02/22/2008	0091	Supplement	Letter (PDF) Review (PDF)	Label is not available on this site.
09/20/2007	0131	Supplement	Label (PDF)	
10/11/2006	0085	Supplement	Label (PDF) Letter (PDF) Review (PDF)	
09/21/2006	0082	Supplement	Label (PDF) Letter (PDF)	
06/20/2006	0074	Supplement	Label (PDF) Letter (PDF) Review (PDF)	
04/18/2006	0067	Supplement	Label (PDF) Letter (PDF)	
09/30/2005	0045	Supplement	Label (PDF) Letter (PDF)	
02/26/2004	000	Approval	Label (PDF) Letter (PDF) Review	

2012

RECENT MAJOR CHANGES

Indications and Usage, Metastatic Breast Cancer (1.3) – Removed	12/2011
Dosage and Administration. Recommended Doses and	12/2011

2008 a 2011

- Metastatic breast cancer, with paclitaxel for treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer. (1.3)

  -Effectiveness based on improvement in progression-free survival. No data available demonstrating improvement in disease-related symptoms or survival with Avastin.

2004

INDICATIONS AND USAGE

AVASTIN, used in combination with intravenous 5-fluorouracil–based chemotherapy, is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Ficha técnica y discusión científica: son útiles para completar los datos del programa MADRE:

ABIRATERONA
En cáncer de próstata metastásico

(Informe para la Comisión de Farmacia y Terapéutica del Hospital Universitario de Getafe)
Fecha 18/01/12

4.2 Indicaciones clínicas formalmente aprobadas y fecha de aprobación

AEMyPS (08/09/11) y EMA (05/09/11): indicado con prednisona o prednisolona para el tratamiento del cáncer de próstata metastásico resistente a la castración en hombres adultos cuya enfermedad ha progresado durante o tras un régimen de quimioterapia basado en docetaxel.

FDA (28/04/11): en combinación con prednisona para el tratamiento de pacientes con cáncer de próstata resistentes a la castración que han recibido una línea previa de tratamiento con docetaxel.

3.- AREA DESCRIPTIVA DEL MEDICAMENTO Y DEL PROBLEMA DE SALUD

3.1 Área descriptiva del medicamento

Nombre genérico:
Nombre comercial:
Laboratorio:
Grupo terapéutico. Denominación: Código ATC:
Vía de administración:
Tipo de dispensación:

4.2 Indicaciones clínicas formalmente aprobadas y fecha de aprobación.

AEMPS: [Fecha de aprobación]
EMA: [Fecha de aprobación]
FDA: [Fecha de aprobación]



3.2 Área descriptiva del problema de salud

3.2.b Tratamiento actual de la enfermedad: evidencias

3.3 Características comparadas con otras alternativas similares

4.- AREA DE ACCIÓN FARMACOLÓGICA.

4.1 Mecanismo de acción.

4.3 Posología, forma de preparación y administración.

4.4 Utilización en poblaciones especiales.

4.5 Farmacocinética.

5.- EVALUACIÓN DE LA EFICACIA.

5.1.a Ensayos clínicos disponibles para la indicación clínica evaluada

5.1.b Variables utilizadas en los ensayos

5.2.a Resultados de los ensayos clínicos

Tabla 1. Modelo general de tabla de resultados de eficacia:

6. EVALUACIÓN DE LA SEGURIDAD.

6.1.b Descripción de los efectos adversos más significativos

2. Evaluaciones realizadas por organismos independientes:

http://www.nice.org.uk/

NHS
National Institute for
Health and Clinical Excellence

NICE National Institute for Health and Care Excellence

NHS
National Health Service

What we do

NICE's role is to improve outcomes for people using the NHS and other public health and social care services. We do this by:

- Producing evidence-based guidance and advice for health, public health and social care practitioners.

- Technology appraisals assess the clinical and cost effectiveness of health technologies, such as new pharmaceutical and biopharmaceutical products, but also include procedures, devices and diagnostic agents.

To ensure our judgements are fair, we use a standard and internationally recognised method to compare different drugs and measure their clinical effectiveness: the quality-adjusted life years measurement (the 'QALY')

Cost effectiveness is expressed as '£ per QALY'.

Each drug is considered on a case-by-case basis. Generally, however, if a treatment costs more than £20,000-30,000 per QALY, then it would not be considered cost effective.



NICE National Institute for Health and Care Excellence

Sign In | Register

Home | News | Get involved | About NICE

Find guidance | NICE Pathways | Quality standards | Into practice | QOF | bevacizumab breast

1 Guidance

1.1 Bevacizumab in combination with a taxane is not recommended for the first-line treatment of metastatic breast cancer.

Abiraterone in combination with prednisone or prednisolone is recommended as an option for the treatment of castration-resistant metastatic prostate cancer in adults, only if:

- their disease has progressed on or after one docetaxel-containing chemotherapy regimen, and
- the manufacturer provides abiraterone with the discount agreed in the patient access scheme.

Omalizumab is recommended as an option for treating severe persistent confirmed allergic IgE-mediated asthma as an add-on to optimised standard therapy in people aged 6 years and older:

- who need continuous or frequent treatment with oral corticosteroids (defined as 4 or more courses in the previous year), **and**
- only if the manufacturer makes omalizumab available with the discount agreed in the patient access scheme.





Informes hospitales, última modificación 4 de abril de 2013:

» Acceso a más de 1000 informes: Enlace

Informes centros de documentación, última modificación 2 de abril de 2013:

» Acceso a más de 900 informes: Enlace

PROGRAMA MADRE 2012, 1 de octubre de 2012:

» Avance Programa MADRE Versión 4.0.: Enlace

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Principio Activo	Indicación	Autor	Tipo informe	Fecha Informe	Fecha Publicación	Enlace
A						
Abacavir + Lamivudina	VIH	H.C.U. de Valladolid		14/02/08	04/08	word
Abatacept	Artritis Reumatoide	GFT de Hospitales de Andalucía	Definitivo	26/06/2008	09/08	PDF
		H.U. de la Vall d´Hebrón			10/08	PDF
		H.U. Móstoles			06/09	PDF
		H.U. Reina Sofía			09/08	PDF
		H.U. Virgen del Rocío	Adaptado	01/09/08	10/08	word
		H.U. Virgen de la Arrixaca	Original	01/10/08	10/08	PDF
Abciximab	Sindrome coronario agudo en ICP	H. Cabueñes (Asturias)	Original	09/06/11	11/11	PDF
Abiraterona-Cabazitaxel	Cáncer de próstata metastásico	H.U. Virgen de la Arrixaca	Original	01/2013	02/13	PDF
		H.U. Virgen del Rocío	Original	07/03/12	03/12	word
Abiraterona	Cáncer de próstata metastásico	H.C.U. de Valladolid	Actualizado	30/10/12	11/12	PDF
		H.U.P. La Fe	Original	02/2012	03/12	PDF
		H. U. Getafe	Original	18/01/12	02/12	word

UpToDate.

Smarter Decisions. Better Care.

UpToDate® is the premier evidence-based clinical decision support resource authored by physicians to help healthcare practitioners make the best decisions at the point of care. By combining the latest clinical knowledge with cutting-edge technology, UpToDate changes the way clinicians practice medicine and has become an indispensable part of clinical workflows in institutions and practices worldwide.

New Search:

All Topics | Search

- **Bevacizumab: Drug information**
- Bevacizumab: Pediatric drug information
- Bevacizumab: Patient drug information
- Launch Lexi-Interact™ Drug Interactions Program
- The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum
- Treatment protocols for non-small cell lung cancer
- Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects
- Treatment protocols for colorectal cancer
- Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects
- Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion
- Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease
- Treatment protocols for gynecologic malignancies
- Bronchial carcinoid tumors: Treatment and prognosis
- Management of recurrent malignant gliomas
- Age-related macular degeneration: Treatment and prevention

XI

Servicios d

MICROMEDEX 2.0

We review, evaluate, and synthesize more than half a million articles annually to provide the best treatment recommendations and guidelines. Our meticulous process and highly trained editorial staff ensure that *Micromedex 2.0* evidence is fully vetted and integrated into our products quickly so you can be confident that your decisions are based on the most current data available.

Entre un o varios términos de búsqueda SEARCH

- Adult Dosing
- Pediatric Dosing
- Dose Adjustments
- FDA-Labeled Indications
- Non-FDA Labeled Indications
- Black Box Warning
- Do Not Confuse
- Contraindications
- Precautions
- Pregnancy Category
- Breast Feeding
- Drug Interactions (single)
- Adverse Effects - Common
- Adverse Effects - Serious
- IV Compatibility (single)
- Drug Images
- US Trade Names
- Class
- Regulatory Status
- Generic Availability
- Mechanism of Action/Pharmacokinetics
- Administration/Monitoring
- How Supplied
- Toxicology - Clinical Effects
- Toxicology - Treatment
- Toxicology - Range of Toxicity
- Clinical Teaching
- References

XI CURSO DE EVALUACIÓN Y SELECCIÓN DE MEDICAMENTOS

Servicios de Farmacia | Hospitales Virgen del Rocío y Son Espases



THE COCHRANE LIBRARY

Independent high-quality evidence for health care decision making

DATABASE OF SYSTEMATIC REVIEWS

Title, Abstract, Keywords | bevacizumab

Anti-angiogenic therapies for metastatic colorectal cancer
Anna Dorothea ADW Wagner , Dirk Arnold , Axel AG Grothey , Johannes Haerting and Susanne Unverzagt
July 2009
Review

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer
Anna Dorothea Wagner , Christoph Thomssen , Johannes Haerting and Susanne Unverzagt
July 2012
Review

Angiogenesis inhibitors for the treatment of ovarian cancer
Kezia Gaitskell , Igor Martinek , Andrew Bryant , Sean Kehoe , Shibani Nicum and Jo Morrison
September 2011
Review

Targeted therapy for advanced renal cell carcinoma
Chris Coppin , Lyly Le , Timothy J Wilt and Christian Kollmannsberger
December 2011
Ns Review

Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy
Jonathan M Smith and David HW Steel
May 2011
Review

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema
Gianni Virgili , Mariacristina Parravano , Francesca Menchini and Massimo Brunetti
December 2012



Resultados de esta búsqueda: BEVACIZUMAB

Mostrar: Resultados en español [22 resultados] | Resultados en inglés [428 resultados] | en total 450



TRATAMIENTO ANGIOGÉNICO PARA EL CÁNCER COLORRECTAL METASTÁSICO

Anna Dorothea ADW Wagner, Dirk Arnold, Axel AG Grothey, Johannes Haerting, Susanne Unverzagt

Esta revisión debería citarse como: Anna Dorothea ADW Wagner, Dirk Arnold, Axel AG Grothey, Johannes Haerting, Susanne Unverzagt. Tratamiento angiogénico para el cáncer colorrectal metastásico (Revision Cochrane traducida). En: *Biblioteca Cochrane Plus* 2009 Número 3. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de *The Cochrane Library*, 2009 Issue 3 Art no. CD005392. Chichester, UK: John Wiley & Sons, Ltd.).

RESUMEN

Antecedentes

Los inhibidores de la angiogénesis se han desarrollado para bloquear la angiogénesis tumoral, y tienen como blanco las células endoteliales vasculares. Aunque algunos inhibidores de la angiogénesis ya han sido aprobados por las autoridades sanitarias y se han integrado con éxito en la asistencia al paciente, muchos otros están todavía en desarrollo y hay que establecer el valor clínico de este enfoque.

Objetivos

Evaluar la eficacia y la toxicidad de los tratamientos antiangiogénicos dirigidos específicamente, añadidos a la quimioterapia, en los pacientes con cáncer colorrectal metastásico. Las variables de evaluación principal primarias son la supervivencia libre de progresión y la supervivencia general. Las tasas de respuesta, la toxicidad y la resecabilidad secundaria fueron las variables de evaluación principal secundarias. Las comparaciones fueron la quimioterapia de primera línea en combinación con los inhibidores de la angiogénesis, con la misma quimioterapia sin inhibidores de la angiogénesis; y la quimioterapia de segunda línea, con la misma quimioterapia sin inhibidor de la angiogénesis.

Estrategia de búsqueda

Se hicieron búsquedas en el Registro Cochrane Central de Ensayos Controlados (Cochrane Central Register of Controlled Trials,

Evaluaciones realizadas por organismos independientes (NICE, Genesis, UptoDate, Micromedex) y las revisiones sistemáticas de la Cochrane: son útiles para completar el programa MADRE

5.3.a Revisiones sistemáticas publicadas

5.4.2 Evaluaciones previas por organismos independientes

A nivel nacional
Otros países



3 Metabuscadores:

http://www.sas.junta-andalucia.es/principal/default.asp

Biblioteca Virtual del Sistema Sanitario Público de Andalucía

- Revistas electrónicas
- Libros electrónicos
- Micromedex
- Uptodate

CINAHL database provides full text for hundreds of nursing and allied health journals

COCHRANE LIBRARY — DATABASE OF SYSTEMATIC REVIEWS

CUIDEN® — BASE DE DATOS DE ENFERMERÍA

embase® BIOMEDICAL ANSWERS — Embase covers over 7,600 biomedical journals

IBECS Índice Bibliográfico Español en Ciencias de la Salud

LILACS literatura científica y técnica en Salud de América Latina y de Caribe.

MEDLINE® U.S. National Library of Medicine

PubMed.gov more than 22 million citations for biomedical literature

SciELO Chile red SciELO ocho paises: Argentina, Brasil, Chile, Colombia, Cuba, España , Portugal y Venezuela,

Resultados de la MetaBúsqueda

Resultados combinados por "**bevacizumab breast**" (1097 resultados)

Visualizar resultados por recursos-e

Formato tabla Formato breve Formato completo

Ordenar por: Relevancia

1- 30 de **56** registros (combinar más)

<< <Anterior Siguiente> >>

No.	Relev.	Autor	Título	Año	Recurso-e	Acción
1		Koutras AK	Angiogenesis as a therapeutic target in breast cancer.	2012	MEDLINE	
			Ítem duplicado			
2		Miles DW	Bevacizumab in breast cancer: fundamental questions remain.	2013	MEDLINE PubMed	
3		Allegra CJ	Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.	2013	MEDLINE	
4		Lang I	Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.	2013	MEDLINE	
5		Lindholm EM	Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.	2012	MEDLINE	
6		Jones DT	Gene expression analysis in human breast cancer associated blood vessels.	2012	MEDLINE	
7		Preusser M	Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.	2012	MEDLINE	
8		De Luca A	Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration.	2012	MEDLINE	
9		Borson R	Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.	2012	MEDLINE	
10		Lang I	Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.	2012	MEDLINE	
11		Criscitiello C	Targeted therapies in breast cancer: are heart and vessels also being targeted?	2012	MEDLINE	
12		Reddy S	Targeting angiogenesis in metastatic breast cancer.	2012	MEDLINE	
13		Volk-Draper LD	Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.	2012	MEDLINE	
14		Sorace AG	Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy.	2012	MEDLINE	

XI CURSO DE EVALUACIÓN Y SELECCIÓN DE MEDICAMENTOS

Servicios de Farmacia | Hospitales Virgen del Rocío y San Espases

Revistas y libros

- Elsevier
- American Medical Association (AMA)
- Primal Pictures (Anatomy)

+ ver más Revistas y Libros

Acceso gratis

Acceso directo al artículo que encontremos con en PubMed (desde Gerión)

- New England Journal of Medicine, The
- Medicina Clínica
- The Lancet
- Jama
- Atencion Primaria
- Journal of Clinical Oncology
- Medicine (Ed. Española)
- Enfermería Clínica
- Journal of Bone and Joint Surgery; American Volume
- Chest
- The American Journal of Gastroenterology
- Pediatrics
- Critical Care Medicine
- Formacion Medica Continuada En Atencion Primaria
- Gastroenterology
- Circulation
- Gastroenterología y Hepatología
- Diabetes Care
- American Journal of Obstetrics and Gynecology
- Obstetrics and Gynecology
- Neurology
- Journal of the American College of Cardiology
- Annals of Internal Medicine
- Hepatology
- Anesthesia & Analgesia
- Clinical Infectious Diseases
- Anales de Pediatría
- Plastic and Reconstructive Surgery
- Radiographics
- The Journal of Clinical Endocrinology and Metabolism

Búsqueda en PubMed desde Gerión (Biblioteca Virtual SSPA):

PubMed.gov
US National Library of Medicine
National Institutes of Health

PubMed | Search | Advanced

Display Settings: Abstract | Send to:

ELSEVIER FULL-TEXT ARTICLE | BV-SSPA

Eur J Pharmacol. 2013 Mar 29. pii: S0014-2999(13)00250-1. doi: 10.1016/j.ejphar.2013.03.035. [Epub ahead of print]

Novel strategies towards the use of anti-angiogenic agents in breast cancer.

Bakker JL, Meijers-Heijboer H, Verheul H.

Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands; Department of Clinical Genetics, Section Oncogenetics, VU University Medical

Save items

Add to Favorites

Prestamo Interbibliotecario/Entrega de documento

Pedir el artículo SOD - Servicio de Obtención de Documentos Go

Texto Completo

Texto completo disponible via DOI Go

Windows Internet Explorer

Total a pagar 5€ por artículo, que se cargarán en la cuenta de su centro o institución. Por favor, confirme su petición

Aceptar | Cancelar



XI CURSO DE EVALUACIÓN Y SELECCIÓN DE MEDICAMENTOS

Servicios de Farmacia | Hospitales Virgen del Rocío y San Espases

4 Ensayos clínicos publicados (fuentes primarias): el ensayo pivotal.



Formas de búsqueda:

- Texto libre.
- Uso de los términos booleanos.
- Pregunta PICO.
- Términos MeSH.
- Uso de corchetes [TI] y [AU] en el texto libre.
- Clinical Queries.

XI CURSO DE EVALUACIÓN Y SELECCIÓN DE MEDICAMENTOS

Servicios de Farmacia | Hospitales Virgen del Rocío y San Espases

Términos booleanos: AND, OR, NOT

OR: “bevacizumab” OR “breast”

Artículos que incluyan “bevacizumab” o “breast” o ambos.

Nº de referencias:



334201

NOT: “bevacizumab” NOT “breast”

Artículos que incluyan “bevacizumab” pero que no tengan el término “breast”.



7086

AND: “bevacizumab” AND “breast”

Artículos que incluyan “bevacizumab” y al mismo tiempo “breast”.



695



Pregunta PICO: estructura de pregunta clínica para iniciar una búsqueda

P: Paciente/Población/Patología/Problema/Edad: “niños con asma”

I: Intervención/Tratamiento Experimental/Exposición: “corticoides inhalados”

C: Control/Tratamiento alternativo (no siempre necesario): “beta agonistas”

O: Outcome/Resultado/Efecto beneficioso o adverso: “retraso del crecimiento”

En niños con asma, el uso de corticoides inhalados es más probable que retarse el crecimiento que el tratamiento estándar con beta agonistas?

Transformamos la pregunta PICO en palabras claves:

PubMed | inhaled corticosteroids AND asthma AND growth delay AND child*

Término truncado: *

Child

Children

Results: 1 to 20 of 22

Growth of asthmatic **children** before long-term treatment with **inhaled corticosteroids**.
4. Moudiou T, Theophilatou D, Priftis K, Papadimitriou A.
J **Asthma**. 2003 Sep;40(6):667-71.
PMID: 14579998 [PubMed - indexed for MEDLINE]
Related citations

Growth problems in **children** with **asthma**.
5. Wolthers OD.
Horm Res. 2002;57 Suppl 2:83-7. Review.
PMID: 12065934 [PubMed - indexed for MEDLINE]
Related citations

The use of **inhaled corticosteroids** in **children** with **asthma**.
6. Kelly HW, Heidarian-Raissy H.
Curr Allergy **Asthma** Rep. 2002 Mar;2(2):133-43. Review.

Término MeSH: Medical Subject Headings: "Método académico"

El término MeSH es el vocabulario controlado que se utiliza para indexar los artículos en PubMed (Medline), proporciona una manera normalizada de recuperar información que puede utilizar diferente terminología para describir el mismo concepto. Contiene encabezados y sub-encabezados. La base de datos consta de 33.000 términos ordenados en estructuras jerárquicas llamadas árboles.

- Strokes
- Apoplexy
- CVA (Cerebrovascular Accident)
- CVAs (Cerebrovascular Accident)
- Cerebrovascular Accident
- Cerebrovascular Accidents
- Cerebrovascular Apoplexy
- Apoplexy, Cerebrovascular
- Cerebrovascular Stroke
- Cerebrovascular Strokes
- Stroke, Cerebrovascular
- Strokes, Cerebrovascular
- Vascular Accident, Brain
- Brain Vascular Accident
- Brain Vascular Accidents
- Vascular Accidents, Brain
- Cerebral Stroke
- Cerebral Strokes
- Stroke, Cerebral
- Strokes, Cerebral
- Stroke, Acute
- Acute Stroke
- Acute Strokes
- Strokes, Acute
- Cerebrovascular Accident, Acute
- Acute Cerebrovascular Accident
- Acute Cerebrovascular Accidents
- Cerebrovascular Accidents, Acute

→ **Stroke MeSH**

Previous Indexing:

- Cerebrovascular Disorders (1964-1999)
- Intracranial Arteriosclerosis (1965-1999)
- Intracranial Embolism and Thrombosis (1965-1999)

All MeSH Categories
Diseases Category
Nervous System Diseases
Central Nervous System Diseases
Brain Diseases
Cerebrovascular Disorders
Stroke
Brain Infarction
Brain Stem Infarctions +
Cerebral Infarction +
Stroke, Lacunar

All MeSH Categories
Diseases Category
Cardiovascular Diseases
Vascular Diseases
Cerebrovascular Disorders
Stroke
Brain Infarction
Brain Stem Infarctions +
Cerebral Infarction +
Stroke, Lacunar

MeSH | accidente cerebrovascular

1. **Cerebrovascular** Trauma
   Penetrating and nonpenetrating traumatic injuries to an extracranial or intracranial blood vessel that supplies the brain. This includes the CAROTID ARTERIES; VERTEBRAL ARTERIES; MENINGEAL ARTERIES; CEREBRAL ARTERIES; veins, and venous sinuses.
   Year introduced: 2000

2. Basal Ganglia **Cerebrovascular** Disease
   A pathological condition caused by impaired blood flow in the basal regions of cerebral hemispheres (BASAL GANGLIA), such as INFARCTION; HEMORRHAGE; or ISCHEMIA in vessels of this brain region including the lateral lenticulostriate arteries. Primary clinical manifestations include involuntary movements (DYSKINESIAS) and muscle weakness (HEMIPARESIS).
   Year introduced: 2000

3. **Cerebrovascular** Disorders
   A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES; or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.

4. **Cerebrovascular** Circulation
   The circulation of blood through the vessels of the BRAIN.
   Year introduced: 1964

5. Stroke
   A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
   Year introduced: 2008 (2000)



Subheadings:

- analysis
- anatomy and histology
- blood
- cerebrospinal fluid
- chemically induced
- classification
- complications
- congenital
- cytology
- diagnosis
- diet therapy
- drug therapy
- economics
- embryology
- enzymology
- epidemiology
- ethnology
- etiology
- genetics
- history
- immunology
- metabolism
- microbiology
- mortality
- nursing
- organization and administration
- parasitology
- pathology
- physiology
- physiopathology
- prevention and control
- psychology
- radiography
- radionuclide imaging
- radiotherapy
- rehabilitation
- statistics and numerical data
- surgery
- therapy
- ultrasonography
- urine
- veterinary
- virology

PubMed search builder

Add to search builder | AND

Search PubMed

Booleano

PubMed search builder

```
"Stroke/therapy"[Mesh]
```

Add to search builder | AND

Search PubMed

PubMed search builder

```
("Stroke/therapy"[Mesh]) AND
"clopidogrel" [Supplementary
Concept]
```

Add to search builder | AND

Search PubMed

Association of **clopidogrel** pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Bellemain-Appaix A, O'Connor SA, Silvain J, Cucherat M, Beygui F, Barthélémy O, Collet JP, Jacq L, Bernasconi F, Montalescot G; ACTION Group.

JAMA. 2012 Dec 19;308(23):2507-16. doi: 10.1001/jama.2012.50788. Review.

PMID: 23287889 [PubMed - indexed for MEDLINE]

Related citations

[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].

Shevelev VI, Kanorsky SG.

Klin Med (Mosk). 2012;90(10):60-3. Russian.

PMID: 23285766 [PubMed - indexed for MEDLINE]

Related citations

Uso de corchetes [TI] y [AU] en el texto libre:

TI – Título: Ej. Clopidogrel[TI]

AU – Autor: EJ. Burton[AU]

No académico, pero muy práctico.

PubMed bevacizumab[TI] diabetic[TI] intravitreal[TI]

RSS Save search Advanced

Display Settings: Summary, 20 per page, Sorted by Recently Added Send to:

Results: 1 to 20 of 175 << First < Prev Page 1 of 9 Next > Last >>

1. Early vitreous hemorrhage after vitrectomy with preoperative **intravitreal bevacizumab** for proliferative **diabetic** retinopathy.
   Sato T, Morita S, Bando H, Sato S, Ikeda T, Emi K.
   Middle East Afr J Ophthalmol. 2013 Jan;20(1):51-5. doi: 10.4103/0974-9233.106387.
   PMID: 23580852 [PubMed - in process] Free PMC Article
   Related citations

2. REPEATED **INTRAVITREAL BEVACIZUMAB** INJECTION WITH AND WITHOUT MACULAR GRID PHOTOCOAGULATION FOR TREATMENT OF DIFFUSE **DIABETIC** MACULAR EDEMA.
   Solaiman KA, Diab MM, Dabour SA.
   Retina. 2013 Mar 27. [Epub ahead of print]
   PMID: 23538584 [PubMed - as supplied by publisher]
   Related citations

3. **Intravitreal bevacizumab** treatment for refractory **diabetic** macular edema.
   Yuksel E, Ozdek S, Yuksel N, Hasanreisoglu B.
   Int Ophthalmol. 2013 Mar 19. [Epub ahead of print]
   PMID: 23508574 [PubMed - as supplied by publisher]
   Related citations

4. **INTRAVITREAL BEVACIZUMAB** (AVASTIN) FOR PERSISTENT NEW VESSELS IN **DIABETIC** RETINOPATHY (IBEPE STUDY): 1-Year Results.
   Cintra LP, Costa RA, Ribeiro JA, Calucci D, Scott IU, Messias A, Jorge R.
   Retina. 2013 Mar 15. [Epub ahead of print]
   PMID: 23508078 [PubMed - as supplied by publisher]
   Related citations



PubMed bevacizumab[TI] diabetic[TI] intravitreal[TI] solaiman[AU]

RSS Save search Advanced

Display Settings: Summary, Sorted by Recently Added Send to:

Results: 2

1. REPEATED **INTRAVITREAL BEVACIZUMAB** INJECTION WITH AND WITHOUT MACULAR GRID PHOTOCOAGULATION FOR TREATMENT OF DIFFUSE **DIABETIC** MACULAR EDEMA.

Solaiman KA, Diab MM, Dabour SA.
Retina. 2013 Mar 27. [Epub ahead of print]
PMID: 23538584 [PubMed - as supplied by publisher]
Related citations

2. **Intravitreal bevacizumab** and/or macular photocoagulation as a primary treatment for diffuse **diabetic** macular edema.

Solaiman KA, Diab MM, Abo-Elenin M.
Retina. 2010 Nov-Dec;30(10):1638-45. doi: 10.1097/IAE.0b013e3181e1ed07.
PMID: 20838357 [PubMed - indexed for MEDLINE]
Related citations

PubMed ICU[TI] INTERACTIONS[TI]

RSS Save search Advanced

Display Settings: Summary, Sorted by Recently Added Send to:

Results: 3

1. Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug **interactions** in the **ICU**.

Spriet I, Meersseman W, de Hoon J, von Winckelmann S, Wilmer A, Willems L.
Intensive Care Med. 2009 Apr;35(4):603-12. doi: 10.1007/s00134-008-1383-2. Epub 2009 Jan 9. Review.
PMID: 19132344 [PubMed - indexed for MEDLINE]
Related citations



NCBI Resources How To

PubMed Clinical Queries

(randomized controlled trial[Publication Type] OR (randomized[Title/Abstract] AND controlled[Title/Abstract] AND trial[Title/Abstract]))

Results of searches on this page are limited to specific clinical research areas. For comprehensive searches, use PubMed directly.

Please enter search term(s)

Clinical Study Categories

This column displays citations filtered to a specific clinical study category and scope. These search filters were developed by Haynes RB et al. See more filter information.

Systematic Reviews

This column displays citations for systematic reviews, meta-analyses, reviews of clinical trials, evidence-based medicine, consensus development conferences, and guidelines. See filter information or additional related sources.

Medical Gene

This column displa
See more filter infor

PubMed Clinical Queries

Results of searches on this page are limited to specific clinical research areas. For comprehensive searches, use PubMed

bevacizumab diabetic macular

Clinical Study Categories

Category: Therapy

Scope: Narrow

Results: 5 of 42

Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration: 52-Week Safety and Efficacy Results of the INTREPID Study.

Jackson TL, Chakravarthy U, Kaiser PK, Slakter JS, Jan E, Bandello F, O'Shaughnessy D, Gertner ME, Danielson L, Moshfeghi DM, et al.
Ophthalmology. 2013 Mar 12; . Epub 2013 Mar 12.

Combined vitrectomy and intravitreal injection versus combined laser and injection for treatment of intractable diffuse diabetic macular edema.

Saeed AM.
Clin Ophthalmol. 2013; 7:283-97. Epub 2013 Feb 14.

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.

Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S, et al.
Br J Ophthalmol. 2013 Mar; 97(3):266-71. Epub 2013 Jan 3.

Systematic Reviews

Results: 5 of 26

Genetic Influences on the Outcome of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-related Macular Degeneration.

Abedi F, Wickremasinghe S, Richardson AJ, Islam AF, Guymer RH, Baird PN.
Ophthalmology. 2013 Apr 9; . Epub 2013 Apr 9.

A systematic review of intravitreal bevacizumab for the treatment of diabetic macular edema.

Fortin P, Mintzes B, Innes M.
CADTH Technol Overv. 2013; 3(1):e3203. Epub 2013 Feb 1.

Current treatments in diabetic macular oedema: systematic review and meta-analysis.

Ford JA, Lois N, Royle P, Clar C, Shyangdan D, Waugh N.
BMJ Open. 2013; 3(3). Epub 2013 Mar 1.

Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.

Mitry D, Bunce C, Charteris D.



5.1.a Ensayos clínicos disponibles para la indicación clínica evaluada

5.3.a Revisiones sistemáticas publicadas

Descripción de la búsqueda bibliográfica: criterios y resultados de la misma.

5.3.b.1 Comparaciones Indirectas publicadas

En fecha xx/xx/xx se realizó búsqueda bibliográfica en Medline. Se dispone de xx ensayos comparaciones indirectas publicados y de xx network metanálisis o MTC.

6. EVALUACIÓN DE LA SEGURIDAD.

6.1.a Descripción de la búsqueda bibliográfica

Descripción de la búsqueda bibliográfica: estrategia y resultados de la misma.



5 Base de datos de Ensayos Clínicos: Clinicaltrials.gov

ClinicalTrials.gov

Search for Studies

Example: "Heart attack" AND "Los Angeles"

bevacizumab AND prostate [Search]

ClinicalTrials.gov currently lists 143,244 studies with locations in all 50 states and in 182 countries.

23 studies found for: bevacizumab AND prostate

Modify this search | How to Use Search Results

List | By Topic | On a Map | Search Details

+ Show Display Options

Download | Subscribe to RSS

☐ Include only open studies ☐ Exclude studies with unknown status

Rank	Status	Study
1	Completed	**Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy** **Conditions:** Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer **Interventions:** Biological: bevacizumab; Other: laboratory biomarker analysis
2	Active, not recruiting	**Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy** **Conditions:** Prostate Cancer; Adenocarcinoma of the Prostate **Interventions:** Drug: Bevacizumab; Drug: Docetaxel
3	Recruiting	**Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer** **Condition:** Prostate Cancer **Intervention:** Drug: RAD001, Docetaxel, Bevacizumab
4	Completed	**Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy** **Condition:** Prostate Cancer **Intervention:** Biological: bevacizumab
5	Active, not recruiting Has Results	**Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer** **Condition:** Prostatic Neoplasms **Interventions:** Drug: Docetaxel; Drug: Thalidomide; Drug: Prednisone; Biological: bevacizumab; Genetic: polymorphism analysis; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: pharmacological study



6 Guías de práctica clínica: Guía Salud, Fisterra, National Guideline Clearinghouse, NCCN.

guiasalud.es
Biblioteca de Guías de Práctica Clínica del Sistema Nacional de Salud

¿Qué es una Guía de Práctica Clínica?

Las Guías de Práctica Clínica (GPC) son un conjunto de "*recomendaciones desarrolladas de forma sistemática para ayudar a profesionales y pacientes a tomar decisiones sobre la atención sanitaria más apropiada, y a seleccionar las opciones diagnósticas o terapéuticas más adecuadas a la hora de abordar un problema de salud o una condición clínica específica*"[1].

Las GPC tienen la potencialidad de reducir la variabilidad y mejorar la práctica clínica.

GUÍAS DE PRÁCTICA CLINICA INCLUIDAS EN EL CATÁLOGO (clasificadas según CIE-9)

Desplegar/recoger todos los menús

- Anomalías congénitas(1)
- Causas externas(6)
- Ciertas enfermedades con origen en el periodo perinatal(1)
- Complicaciones del embarazo, parto y puerperio(0)
- Enfermedades de la piel y del tejido subcutáneo(9)
- Enfermedades de la sangre y de los órganos hematopoyéticos(2)
- Enfermedades del aparato digestivo(15)
- Enfermedades del aparato genitourinario(10)
- Enfermedades del aparato respiratorio(12)
- Enfermedades del sistema circulatorio(19)
- Enfermedades del sistema nervioso y de los órganos de los sentidos(12)
- Enfermedades del sistema osteo-mioarticular y tejido conectivo(9)
- Enfermedades infecciosas y parasitarias(10)
- Enfermedades endocrinas, de la nutrición y metabólicas y trastornos de la inmunidad(10)
- Factores que influyen en la Salud(6)
- Lesiones y envenenamientos(1)
- Neoplasias(23)
- Síntomas, signos y estados mal definidos(8)
- Trastornos mentales(21)

Buscar **diabetes** Avanzado »



Buscar **diabetes** Avanzado »

Ordenación

Criterio **Seleccionar Criterio**

Orden **Seleccionar Orden**

Buscar

Mostrando 3 resultados.

Guía de Práctica Clínica sobre Diabetes Mellitus Tipo 1

Situación: Incluida
Fecha de edición: 01/05/2012
Entidades elaboradoras: Agencia de Evaluación de Tecnologías Sanitarias del País Vasco-Osteba

Vista previa
GuíaSalud Biblioteca - 15/04/2013

Guía de práctica clínica sobre el manejo de los lípidos como factor de riesgo cardiovascular

Situación: Caducada
Fecha de edición: 01/01/2008
Entidades elaboradoras: Osakidetza y Departamento de Sanidad. Administración de la CC.AA. del País Vasco

Vista previa
GuíaSalud Biblioteca - 01/03/2013

Guía de Práctica Clínica sobre Diabetes Tipo 2

Situación: Incluida
Fecha de edición: 01/07/2008
Entidades elaboradoras: Agencia de Evaluación de Tecnologías Sanitarias del País Vasco - Osteba

fisterra.com
Atención Primaria en la Red

Guías clínicas | Ayuda en consulta | Herramientas | Formación | Tienda

Índice por especialidad | Índice alfabético

Buscar

Inicio > Guías clínicas

Guías clínicas

Las guías de práctica clínica de **Fisterra**, son recomendaciones para profesionales de la salud desarrolladas de forma sistemática para orientar al profesional a tomar las decisiones adecuadas cuando el paciente tiene una enfermedad determinada.

En fisterra.com disponemos de **473 guías clínicas** de las cuales **9** pueden consultarse **en abierto** y para las restantes es necesario registro.

GUÍAS CLÍNICAS
Total: 473

ALGORITMOS
Total: 233

IMÁGENES
Total: 403

MEDICAMENTOS
Total: 1043

INFORMACIÓN PARA PACIENTES
Total: 138

TÉCNICAS ATENCIÓN PRIMARIA
Total: 79

Subscripción anual

XI CURSO DE EVALUACIÓN Y SELECCIÓN DE MEDICAMENTOS

bevacizumab | Buscar


AHRQ Agency for Healthcare Research and Quality
Advancing Excellence in Health Care
www.ahrq.gov/
Visit: National Quality Measures Clearinghouse | Health Care Innovations Exchange | AHRQ Home
Sign In
National Guideline Clearinghouse
Help | RSS | Subscribe to weekly e-mail | Site map | Contact us | For web developers
bevacizumab
Search
Search Tips Advanced Search About Search
Home
Guidelines
Expert Commentaries
Guideline Syntheses
Guideline Matrix
Guideline Resources
Annotated Bibliographies
Compare Guidelines
FAQ
Submit Guidelines
About
My NGC
< Back
'bevacizumab'
Run an advanced search on this term
Search within:
GO
Sort results by: Relevance (what's this?) Publication date
Filter results by: All Years
1-20 of 29 Next >
Compare Guidelines
1. The use of bevacizumab in metastatic breast cancer. 2009 Apr 17. NGC:007694
Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
2. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first -line) for the treatment of advanced and/or metastatic renal cell carcinoma. 2009 Aug. NGC:007628
National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
3. Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer. 2012 Aug. NGC:009311
National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
4. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer. 2009 May 22 (revised 2010 Feb 3). NGC:007692
Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
5. The use of inhibitors of angiogenesis in patients with inoperable locally advanced or metastatic renal cell cancer: guideline recommendations. 2009 Apr 30. NGC:007277
Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
6. Age-related macular degeneration. 1998 Sep (revised 2008 Sep; republished 2011). NGC:007151
American Academy of Ophthalmology - Medical Specialty Society. View all guidelines by the developer(s)

Guideline Title

The use of bevacizumab in metastatic breast cancer.



You are leaving the National Guideline Clearinghouse

National Comprehensive Cancer Network

Your Best Resource in the Fight Against Cancer®

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world's leading cancer centers is dedicated to improving the quality and effectiveness of care provided to patients with cancer.

NCCN GUIDELINES FOR TREATMENT OF CANCER BY SITE

Acute Lymphoblastic Leukemia ▸

Acute Myeloid Leukemia ▸

Anal Carcinoma ▸

Bladder Cancer ▸

Bone Cancer ▸

Breast Cancer ▸

Cancer of Unknown Primary (See Occult Primary)

Central Nervous System Cancers ▸

Cervical Cancer ▸

Chronic Myelogenous Leukemia ▸

Colon/Rectal Cancer

- Colon Cancer ▸
- Rectal Cancer ▸

Cutaneous Melanoma (See Melanoma)

Endometrial Cancer (See Uterine Neoplasms)

Esophageal and Esophagogastric Junction Cancers

Fallopian Tube Cancer (See Ovarian Cancer)

Gastric Cancer ▾

PDF NCCN Guidelines

INT NCCN International Translations/Adaptations

Head and Neck Cancers ▸

Hepatobiliary Cancers ▸

Hodgkin Lymphoma ▸

Kidney Cancer ▸

Malignant Pleural Mesothelioma ▸

Melanoma ▸

Multiple Myeloma/Other Plasma Cell Neoplasms

- Multiple Myeloma ▸
- Systemic Light Chain Amyloidosis ▸
- Waldenström's Macroglobulinemia / Lymphoplasma

Myelodysplastic Syndromes ▸

Neuroendocrine Tumors ▸

Non-Hodgkin's Lymphomas ▸

Non-Melanoma Skin Cancers

- Basal and Squamous Cell Skin Cancers ▸
- Dermatofibrosarcoma Protuberans ▸
- Merkel Cell Carcinoma ▸

Non-Small Cell Lung Cancer ▸

Occult Primary ▸

Ovarian Cancer ▸

Pancreatic Adenocarcinoma ▸

Penile Cancer ▸

Primary Peritoneal Cancer (See Ovarian Cancer)

Prostate Cancer ▸ 

Small Cell Lung Cancer ▸

Soft Tissue Sarcoma ▸

Testicular Cancer ▸

Thymomas and Thymic Carcinomas ▸

Thyroid Carcinoma ▸

Uterine Neoplasms ▸

NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline®)

Prostate Cancer

Version 2.2013

NCCN.org

PDF

ADVANCED DISEASE: ADDITIONAL SYSTEMIC THERAPY FOR CASTRATION-RECURRENT PROSTATE CANCER



[j] See Principles of Androgen Deprivation Therapy (PROS-E).

[p] Frequency of imaging should be based on individual risk, age, PSA velocity, Gleason score, and overall health.

[q] See Principles of Chemotherapy/Immunotherapy (PROS-F).

[s] Sipuleucel-T is appropriate for asymptomatic or minimally symptomatic patients with ECOG performance status 0-1. Sipuleucel-T is not indicated in patients with hepatic metastases or life expectancy <6 months.

[t] For patients who are not candidates for docetaxel-based regimens.

[u] Although most patients without symptoms are not treated with chemotherapy, the survival benefit reported for docetaxel applies to those with or without symptoms. Docetaxel may be considered for patients with signs of rapid progression or hepatic metastases despite lack of symptoms.

Note: All recommendations are category 2A unless otherwise indicated.

Las guías de práctica clínica (Guía Salud, Fisterra, National Guideline Clearinghouse, NCCN): son útiles para completar el programa MADRE

3.2 Área descriptiva del problema de salud

3.2.b Tratamiento actual de la enfermedad: evidencias

3.3 Características comparadas con otras alternativas similares

5.4.1 Guías de Práctica clínica



7 Literatura gris e Internet invisible: Metabuscador Scirus

Internet visible (superficial) 167 TB → Google España

Internet invisible (profundo) 7.500 TB → SCIRUS for scientific information only



Literatura gris: El conjunto de documentos, de muy diversa tipología, que no son editados o que se publican pero distribuyen a través de canales poco convencionales (tesis doctorales, actas de congresos, informes de investigación, memorias, proyectos, patentes, normas, etc.).

Advanced search

Dates — Only show results published between: before 1900 and 2014

Information types — Only show results that are

- [x] Any information type
- [ ] Abstracts
- [ ] Articles
- [ ] Articles in Press
- [ ] Books
- [ ] Conferences
- [ ] Patents
- [ ] Preprints
- [ ] Reviews
- [ ] Scientist homepages
- [ ] Theses and Dissertations

File formats — Only show results that are

- [x] Any format
- [ ] PDF
- [ ] HTML
- [ ] Word

List more file types

Content sources — Only show results from

Journal sources
- [x] All
- [ ] American Physical Society
- [ ] BioMed Central
- [ ] BMJ Group
- [ ] Crystallography Journals Online
- [ ] Hindawi Publishing Corporation

List more sources

Preferred Web sources
- [x] All
- [ ] E-Print ArXiv
- [ ] Caltech
- [ ] CogPrints
- [ ] Curator
- [ ] Department of Energy

List more sources

- [x] The rest of the scientific web

Subject areas — Only show results in

- [x] All subject areas
- [ ] Agricultural and Biological Sciences
- [ ] Astronomy
- [ ] Chemistry and Chemical Engineering
- [ ] Computer Science
- [ ] Earth and Planetary Sciences
- [ ] Economics, Business and Management
- [ ] Engineering, Energy and Technology
- [ ] Environmental Sciences
- [ ] Languages and Linguistics
- [ ] Law
- [ ] Life Sciences
- [ ] Materials Science
- [ ] Mathematics
- [ ] Medicine
- [ ] Neuroscience
- [ ] Pharmacology
- [ ] Physics
- [ ] Psychology
- [ ] Social and Behavioral Sciences
- [ ] Sociology

XI CURSO DE EVALUACIÓN Y SELECCIÓN DE MEDICAMENTOS

Servicios de Farmacia | Hospitales Virgen del Rocío y San Espases

How To

PubMed | bevacizumab prostate

RSS Save search Advanced

Display Settings: Summary, 20 per page, Sorted by Recently Added

Results: 1 to 20 of 94

<< First < Prev

Google | bevacizumab prostate

Académico

Aproximadamente 15.400 resultados (0,05 s)

SCIRUS
for scientific information only

bevacizumab prostate | Search

1-10 of 34,009 hits for **bevacizumab prostate**

Email, Save or Export checked results

Filter search results by

Content sources

Journal sources (4,515)
- ScienceDirect (2,840)
- Pubmed Central (648)
- Springer (356)

more ▹

Preferred web (7,562)
- Patent Offices (6,853)
- NDLTD (357)
- Digital Archives (146)

more ▹

Other web (21,932)

File types
- HTML (31,764)
- PDF (4,963)
- Word (70)

1. Phase 2 study of neoadjuvant docetaxel plus **bevaciz**
Ross, Robert W / Galsky, Matthew D / Febbo, Phil /
doi:10.1002/cncr.27416
...high-risk localized **prostate** cancer remains inadequa
docetaxel and **bevacizumab** is safe, and results...high
MEDLINE/PubMed Citation on PubMed
similar results

2. **Bevacizumab** for Hormone-Refractory **Prostate** Cancer
Nov 2012
...for information about **prostate** cancer. **Bevacizumab**
Refractory...Adenocarcinoma of the **Prostate** (CALGB-9
[http://www.cancer.gov/clinicaltrials/featured/trials/c...
similar results

3. **Bevacizumab** treatment of **prostate** cancer.
Small, Alexander C / Oh, William K, *Expert opinion on*
doi:10.1517/14712598.2012.704015
...clinical trials for **bevacizumab** in **prostate** cancer. Ov
prostate cancer.
MEDLINE/PubMed Citation on PubMed

XI CURSO DE EVALUACIÓN Y SELECCIÓN DE MEDICAMENTOS

Servicios de Farmacia | Hospitales Virgen del Rocío y San Espases

Gracias por la atención prestada